Stock Market Today: Nifty Ends Below 25,500, Sensex Settles Nearly 200 Points Lower As RIL, ICICI Bank Drag
That's all for NDTV Profit's real-time market coverage. Thank you!

KEY HIGHLIGHTS
Rupee Closes Stronger Against US Dollar
Stock Market Today: Viceroy Research On Vedanta
Stock Market Live Update: Vedanta Share Price Plunges After Viceroy Research Shorts On Its Parent Firm's Debt
ICICI Prudential AMC IPO: Promoter To Sell Shares Worth Rs 10,300 Crore
Primary Market Update: Crizac Lists At Rs 281.05 On NSE
- Oldest First
Market At Close: Nifty Settles Below 25,500
Nifty close below the 25,500 mark, snaps 3-day gaining streak.
HCL Tech and Tata Steel are the top losers in Nifty.
Tata Steel fell 3% after reporting muted quarterly business update.
Benchmark underperformed Broader Market indices.
Nifty Realty becomes the top losing sector followed by Metal and Oil and Gas.
Brigade Enterprises and The Phoenix Mills fell the most in the Nifty Realty.
Nifty Realty, Metal and Oil and Gas fell by more than 1% each.
Nifty Midcap 150 fall for the 4th consecutive day.
Vedanta recovers from lows after it clarify that Viceroy report is baseless.
Nifty smallcap 250, Pharma snaps 2-day losing streak.
Nifty Auto snaps 3-day losing streak.
Nifty Oil and Gas snaps 4-day gaining streak.
Nifty PSU Bank, Media fell for the 3-day in a row.
Nifty Metal fell for the 5th day in a row.
Nifty Realty snaps 3-day gaining streak.
Nifty Financial services gains fo













Rupee Closes Stronger Against US Dollar
Rupee closed 2 paise stronger against US Dollar at 85.68
It closed at 85.70 a dollar on Tuesday.
Source: Bloomberg

Stock Market Today: Jindal Saw Extends Managing Director's Tenure By 5 Years
Jindal Saw Ltd. has re-appointed Sminu Jindal as Managing Director for an additional five-year term.
Stock Market Today: Gabriel India To Buy Stakes In JV Jinhap Automotive
Gabriel India is set to sign a joint venture agreement with Jinos for the fasteners business, acquiring a 51% stake in Jinhap Automotive India for Rs 26.8 crore.
Stock Market Live Update: Lupin In License & Supply Pact To Commercialise Biosimilar Certolizumab
Lupin has entered into a license and supply agreement for the commercialization of biosimilar Certolizumab Pegol, used to treat rheumatoid arthritis. The company will receive an initial payment of $10 million upon execution of the pact.